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Aim: The aim is to report the long-term outcomes of preoperative cisplatin and fluo-
rouracil plus docetaxel (DCF) vs Adriamycin (ACF) for resectable esophageal squa-
mous cell carcinoma (ESCC). Previously, this trial showed that DCF is associated with 
prolonged recurrence-free survival (RFS).
Methods: Patients were randomly assigned to two cycles of ACF (35 mg/m2 of 
Adriamycin, 70 mg/m2 of cisplatin intravenously on day 1, and 700 mg/m2 of fluoro-
uracil infusion for 7 days) every 4 weeks or DCF (70 mg/m2 of docetaxel, 70 mg/m2 
of cisplatin intravenously on day 1, and 700 mg/m2 of fluorouracil infusion for 5 days) 
every 3 weeks, followed by surgery. The primary endpoint was RFS. The secondary 
endpoint was overall survival (OS).
Results: Between October 2011 and October 2013, 162 patients at 10 institutions 
were enrolled in the study, 162 of whom were eligible and randomly assigned to 
the two groups. The median follow-up for surviving patients was 69.8 months. The 
5-year RFS was significantly better in the DCF group than in the ACF group (59.9% vs 
40.7%, hazard ratio [HR] 0.55; 95% confidence interval [CI], 0.35-0.86; P = .009) and 
the 5-year OS was significantly better in the DCF group than in the ACF group (63.5% 
vs 49.4%, HR, 0.61; 95% CI, 0.38-0.96; P = .03). The benefit of DCF chemotherapy 
on survival was significantly greater in the subgroups with more advanced clinical T 
and N stage.
Conclusions: Cisplatin and fluorouracil plus docetaxel are associated with better RFS 
and OS than ACF in resectable ESCC patients.
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1  | INTRODUC TION
Esophageal cancer is an aggressive disease with a high degree of 
both distant and regional metastasis at comparatively early stages.1 
Neoadjuvant therapy, or adjuvant therapy followed by surgery, 
is widely used to improve the prognosis of patients with resect-
able esophageal squamous cell carcinoma (ESCC).2-4 Neoadjuvant 
chemoradiotherapy is currently regarded as the standard treatment 
for patients with resectable esophageal cancer in Western coun-
tries.5-8 On the other hand, neoadjuvant chemotherapy such as 
cisplatin and fluorouracil (CF) chemotherapy is also regarded as an 
alternative treatment in Asia. However, CF regimen has a low re-
sponse rate and controversial survival benefit.9-14
Triplet regimens with Adriamycin, epirubicin, or docetaxel in 
addition to CF were recently reported to be more effective in pa-
tients with advanced esophageal cancer rather than doublet reg-
imen.15-19 Thus, we planned a clinical trial of triplet neoadjuvant 
chemotherapy regimens so that we can select the best chemo-
therapy regimen in order to compare with chemoradiotherapy in 
future.
The randomized controlled chemotherapy for esophageal can-
cer followed by surgery trial (OGSG1003) compared two regimens 
of neoadjuvant chemotherapy (CF plus Adriamycin (ACF) vs CF plus 
docetaxel (DCF) plus surgery.20 A total of 162 patients at 10 insti-
tutions were enrolled between November 2010 and October 2012. 
The initial results of this trial showed that DCF chemotherapy is as-
sociated with prolonged recurrence-free survival (RFS) compared to 
ACF.21 Here, we report long-term follow-up results with analysis of 
the primary endpoint, RFS, as well as secondary endpoints such as 
overall survival (OS) and recurrence patterns.
2  | METHODS
2.1 | Patients
Full details of the eligibility criteria and pre-treatment evaluation 
were reported previously.14 Briefly, eligible patients were aged 
20 years or older with performance status ≥1, histologically con-
firmed squamous cell carcinoma of the thoracic esophagus, and 
adequate bone marrow, renal, hepatic, and pulmonary function. 
Patients with clinical stage Ib to IIIB, stage IIIC without T4b, or 
stage IV disease based on only supraclavicular lymph node metas-
tasis were eligible. All patients provided written informed consent 
before enrolment. The institutional review board at each participat-
ing institution approved the study protocol. This study was regis-
tered with the University Hospital Medical Information Network 
Clinical Trials Registry (UMIN-CTR) of Japan (identification number 
UMIN000004555/000004616).
2.2 | Treatment
The randomization scheme was described previously.14 Patients 
were stratified by institution and clinical N stage. They were then 
randomly assigned to either ACF chemotherapy followed by sur-
gery (ACF group) or DCF chemotherapy followed by surgery (DCF 
group). ACF chemotherapy consisted of two cycles of Adriamycin 
(35 mg/m2) and cisplatin (70 mg/m2) as a 1-hour intravenous in-
fusion and fluorouracil (5-FU, 700 mg/m2/d) as a continuous 
intravenous infusion for 7 days (days 1-7) every 4 weeks. DCF 
chemotherapy consisted of two cycles of docetaxel (70 mg/m2) 
and cisplatin (70 mg/m2) as a 1-hour intravenous infusion and 5-FU 
(700 mg/m2/d) as a continuous intravenous infusion for 5 days 
(days 1-5) every 3 weeks.
Surgery was scheduled within 6 weeks after completing the 
last cycle of chemotherapy in both groups. Surgery consisted of 
subtotal esophagectomy through a right thoracotomy or video-as-
sisted thoracoscopic surgery. Transhiatal esophagectomy was not 
performed in this trial. Each surgeon decided on the surgical pro-
cedure, including whether cervical lymphadenectomy was added, 
reconstruction route, and whether organ reconstruction was per-
formed, in accordance with the location of the tumor and institu-
tional practice.
2.3 | Follow-up
Patients were seen every 3 months during the first 2 years after the 
date of random assignment, every 6 months for the next 3 years, and 
annually thereafter. Disease recurrence was defined as locoregional 
(at the primary site including the anastomosis, regional lymph nodes, 
and supraclavicular lymph nodes) or distant (including non-regional 
lymph nodes except for the supraclavicular lymph nodes or distant 
organs). The study protocol stipulated that postoperative adjuvant 
chemotherapy or chemoradiotherapy was not performed.
2.4 | Statistical analysis
Data were analyzed according to the intention-to-treat principle. OS 
was measured from the date of randomization to the date of death 
due to any cause or last follow-up. RFS was measured from the date 
of randomization to the date of first evidence of recurrence, death 
due to any cause, or last follow-up in patients without recurrence. 
We used the Kaplan–Meier method to estimate OS and RFS and the 
log-rank test to compare differences across groups. Univariate Cox 
regression modeling was used to analyze differences in recurrence-
free interval between treatment groups. Deaths from non-disease-
related causes were censored. Recurrence was defined as recurrence 
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in patients with R0 resection and either locoregional residual disease 
after protocol treatment or distant residual disease during or after 
protocol treatment in patients with R0 resection or patients who did 
not undergo resection.
Hazard ratios (HRs) for DCF and ACF and 95% confidence in-
tervals (CIs) were estimated using Cox proportional hazards re-
gression for each subgroup. Differences in OS between the two 
treatment groups were tested. Subgroups were predefined ac-
cording to baseline patient characteristics such as age, sex, per-
formance status, location of the primary tumor, clinical T stage, 




From November 2010 to October 2012, a total of 162 patients with 
resectable esophageal squamous cell carcinoma were randomly al-
located to the two treatment groups in a 1:1 ratio (Figure 1) and in-
cluded in the intention-to-treat analysis. Since the initial reporting 
of this study, no additional information became available regarding 
baseline characteristics, which were well-balanced between the two 
treatment groups (Table 1). Histological tumor stage and response 
evaluation are summarized in Table 2.
The final day of follow-up was January 2018, guaranteeing a 
minimum follow-up of 5 years for all patients included in the anal-
ysis except for one patient in the DCF group who was lost to fol-
low-up after moving at 26 months after randomization. The median 
follow-up for surviving patients was 69.8 months.
3.2 | Recurrence pattern
Of 81 eligible patients randomly assigned to the DCF group, 78 un-
derwent surgery: 75 (93%) patients underwent R0 resection and 
three (3.7%) underwent R1/2 resection. Among the 81 patients ran-
domly assigned to the ACF group, 74 underwent surgery: 70 (86%) 
patients underwent R0 resection, three (3.7%) patients underwent 
R1/2 resection, and one (1.2%) patient underwent exploratory 
thoracotomy.
Table 3 presents the pattern of first recurrence in patients who 
underwent R0 resection or pattern of residual disease in patients 
who underwent R1/2 resection or those who did not undergo sur-
gery. Recurrence occurred in 76 patients (47%). Four patients ex-
perienced recurrence since the previous report. In the DCF group, 
29 patients had recurrence or residual disease: 18 had locoregional 
disease, 17 had distant disease, and six had both locoregional and 
distant disease. In the ACF group, 47 patients had recurrence or re-
sidual disease: 29 had locoregional disease, 26 had distant disease, 
and eight had both locoregional and distant disease. Compared to 
the ACF group, the DCF group had significantly higher control rates 
for locoregional and distant disease.
After recurrence, 37 patients (79%) had treatment in the ACF 
group while 25 patients (86%) had treatment in the DCF group 
(P = .547). As first treatment after recurrence, 16 patients (34%) 
had chemotherapy, 14 (30%) had chemoradiotherapy, five (11%) 
had radiotherapy, and two (4%) had surgery in the ACF group. On 
the other hand, 10 patients (34%) had chemoradiotherapy, nine 
(31%) had chemotherapy, four (14%) had radiotherapy, and two 
(7%) had surgery in the DCF group. The difference in the first 
treatment after recurrence difference was not seen between two 
groups (P = .934).
F I G U R E  1   CONSORT diagram
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3.3 | Survival
At the time of this analysis, the median follow-up was 61 months in the 
ACF group and 65 months in the DCF group. The 5-year RFS was 40.7% 
in the ACF group and 59.9% in the DCF group (Figure 2A). Compared 
with the ACF group, the DCF group had a significantly higher likeli-
hood of RFS (HR, 0.55; 95% CI, 0.35-0.86; P = .012). The 5-year OS 
was 49.4% in the ACF group and 63.5% in the DCF group (Figure 2B). 
Compared with the ACF group, the DCF group also had a significantly 
higher likelihood of OS (HR, 0.61; 95% CI, 0.38-0.96; P = .034).
We found no differences in OS between patients receiving 
ACF vs DCF by age, sex, performance status, and tumor location 
(Figure 3). On the other hand, the OS of patients with advanced 
clinical T (cT3 or cT4) stage and N (cN2 or cN3) stage who under-
went DCF was significantly better than those who underwent ACF. 
However, we found no differences in OS between the two groups 
among those with early clinical T (cT1 or cT2) stage and N (cN0 or 
cN1) stage.
Figure 4 presents the OS curves for patients with cStage I or II 
(Figure 4A) and cStage III or IV (Figure 4B) cancer on the basis of 
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Abbreviations: ACF, adriamycin + cisplatin and fluorouracil; DCF, 
docetaxel + cisplatin and fluorouracil; ECOG, Eastern Cooperative 
Oncology Group.




(n = 78) P value
pT stage
0 0 (0%) 11 (14%) .008
1 16 (22%) 17 (22%)
2 18 (25%) 13 (17%)
3 34 (47%) 33 (42%)
4 5 (7%) 3 (5%)
pN stage
0 27 (37%) 33 (42%) .367
1 25 (34%) 20 (26%)
2 14 (19%) 21 (27%)
3 7 (10%) 4 (5%)
pM stage
0 61 (84%) 72 (92%) .092
1 12 (16%) 6 (8%)
pStage
0 0 (0%) 7 (9%) .015
I 16 (22%) 14 (18%)
II 16 (22%) 21 (27%)
III 29 (40%) 30 (39%)
IV 12 (16%) 6 (8%)
Residual tumor
R0 70 (96%) 75 (96%) .932
R1/2 3 (4%) 3 (4%)
Histopathological tumor response
0 11 (15%) 2 (3%) <.001
1a 35 (48%) 22 (28%)
1b 14 (19%) 21 (27%)
2 13 (18%) 22 (28%)
3 0 (0%) 11 (14%)
Abbreviations: ACF, adriamycin + cisplatin and fluorouracil; DCF, 
docetaxel + cisplatin and fluorouracil.
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preoperative chemotherapy regimen (ACF vs DCF). In patients with 
cStage I or II disease, the 5-year OS was 67.9% in the ACF group and 
73.9% in the DCF group (P = .439). In patients with cStage III or IV 
disease, the 5-year OS was 39.6% in the ACF group and 59.3% in the 
DCF group. Patients who underwent preoperative DCF followed by 
surgery had significantly better survival than those who underwent 
preoperative ACF (HR, 0.55; 95% CI, 0.33-0.92; P = .020).
4  | DISCUSSION
These long-term results confirm the initial report that preopera-
tive DCF chemotherapy followed by surgery is associated with pro-
longed RFS when compared to preoperative ACF chemotherapy 
followed by surgery. The present results also show that compared 
with preoperative ACF chemotherapy, DCF chemotherapy improves 
OS when followed by surgery. Furthermore, there was significantly 
less locoregional and distant recurrence in the DCF group than in 
the ACF group. The DCF regimen may be a candidate neoadjuvant 
therapy for resectable ESCC.
The present study showed that neoadjuvant DCF is superior to 
neoadjuvant ACF in terms of RFS and OS. To the best of our knowl-
edge, this is the first prospective comparison of superiority for pre-
operative chemotherapy regimens for esophageal cancer in terms 
of long-term prognosis. To date, one report has compared prospec-
tive preoperative chemotherapy regimens for esophageal cancer. 
Alderson et al22 compared preoperative cisplatin plus 5-FU with 
epirubicin, cisplatin, and capecitabine (ECX) followed by surgery in 
patients with esophageal adenocarcinoma in the phase 3 UK MRC 
OE05 trial. They showed that the ECX group had a higher patho-
logical treatment effect for primary esophageal lesions and a higher 
pN0 rate. However, they also showed that the median survival was 
23.4 months in the CF group and 26.1 months in the ECX group, 
which was similar. Therefore, they concluded that preoperative 
ECX does not prolong survival compared with preoperative CF. The 
differences between their results and our results might be due to 
differences in the rate of curative resection as well as histological 
type. Indeed, in UK MRC OE05, the ECX group had a more patho-
logical effect rather than CF group, but the proportion of patients 
with Mandard 1-2 disease was as low as 17%. Among the 446 pa-
tients assigned to the ECX group, R0 resection was possible in 223 
patients, only 50% of the total. On the other hand, the R0 resection 
rate in the DCF group in this study was 93%, which may indicate that 
chemotherapy was more likely to lead to a difference in resectability.
The subgroup analysis of this study showed that DCF is superior 
to ACF in terms OS in patients with clinical Stage 3 or 4 disease, but 
DCF and ACF had similar effects in patients with clinical stage 1 or 
2 disease. This might be partly because there was a difference in 
clinical response between patients with clinical stage 1 or 2 vs 3 or 






(n = 81) P value
Overall 76 47 (58%) 29 (36%) .004
Locoregional 47 29 (36%) 18 (22%) .030
Distant 43 26 (32%) 17 (21%) .041
Lymph node 8 6 (7%) 2 (2%) .277
Liver 11 8 (10%) 3 (4%) .210
Lung 10 3 (4%) 7 (9%) .328
Bone 6 4 (5%) 2 (2%) .681
Brain 1 1 (1%) 0 (0%) 1.000
Pleura 11 7 (9%) 4 (5%) .534
Other 5 2 (3%) 3 (4%) 1.000
Abbreviations: ACF, Adriamycin + cisplatin and fluorouracil; DCF, 
docetaxel + cisplatin and fluorouracil.
F I G U R E  2   Kaplan-Meier estimates of (A) recurrence-free and 
(B) overall survival. A, The 5-year recurrence-free survival (RFS) was 
40.7% in the Adriamycin + cisplatin and fluorouracil (ACF) group 
and 59.9% in the cisplatin and fluorouracil plus docetaxel (DCF) 
group (HR, 0.55; 95% CI, 0.35-0.86; P = .012). B, The 5-year OS was 
49.4% in the ACF group and 63.5% in the DCF group (HR, 0.61; 95% 
CI, 0.38-0.96; P = .034)
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4 disease. Indeed, in patients with stage 1 or 2 disease, the response 
rates for ECF and DCF were equivalent at 71% and 74%, respec-
tively, whereas in patients with stage 3 or 4 disease, the response 
rates for ECF and DCF were 45% and 68%, respectively. Based on 
these points mentioned above, DCF is a good candidate for preop-
erative chemotherapy for stage 3 and 4 disease, but a slightly less 
toxic regimen may be considered for stage 1 and 2 disease from the 
viewpoint of toxicity.
The present study revealed that the DCF group had less post-
operative local recurrence than the ACF group. This can be ex-
plained by the fact that DCF has a stronger effect on primary 
tumors than ACF. In fact, the pathological treatment effect was 
17.8% for ACF vs 42.3% for DCF in patients with grade ≥2 disease. 
Pathological T stage was also significantly lower in the DCF group 
than in the ACF group. Our results were consistent with previous 
results. Oppedijk et al8 analyzed the pattern of recurrence after 
preoperative chemoradiation followed by surgery in the CROSS 
trial. Their results suggested that local relapse was less likely to 
occur when the response to preoperative chemoradiotherapy is 
more effective.
This study also indicated that preoperative DCF is significantly 
more effective than ACF in preventing distant metastatic recur-
rence. Although individual recurrence sites were similar, recurrences 
in distant lymph nodes and liver and metastases in the pleura tended 
to be smaller in the DCF group. This result indicates that preoper-
ative chemotherapy regimens with higher clinical response and 
pathological effect are more beneficial in suppressing recurrence of 
distant metastasis.
In the present study, recurrence occurred in 76 patients. Fifty-
two (82%) of the recurrent patients had treatment. First treatment 
after recurrence between two groups was similar. Additionally, after 
recurrence, the rates of use of regimens containing docetaxel were 
similar in both groups (38% vs 31%). Thus, in this study, contents 
of preoperative treatment did not affect choice of treatment after 
recurrence.
This study has several limitations. This was a phase 2 trial with 
only a small number of patients. Thus, the results cannot be used 
F I G U R E  3   Forest plot of hazard ratios 
(HRs) and 95% confidence intervals 
(CIs) for survival in 162 patients with 
esophageal cancer stratified by baseline 
characteristics
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to determine standards for preoperative treatment. The NExT trial 
(JCOG1109), a randomized controlled trial of preoperative chemo-
radiotherapy and chemotherapy, is currently ongoing in Japan. The 
results will provide evidence of the most appropriate preoperative 
treatment for ESCC.23
In conclusion, this study showed that, compared to ACF che-
motherapy, DCF chemotherapy is associated with prolonged RFS 
and OS for patients with resectable ESCC. Thus, DCF chemo-
therapy may be a candidate neoadjuvant therapy for resectable 
ESCC.
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